Citigroup started coverage on shares of Millendo Therapeutics (NASDAQ:MLND) in a research report released on Monday, The Fly reports. The firm issued an outperform rating and a $26.00 price target on the stock.
Several other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of ExlService from a hold rating to a sell rating in a research note on Wednesday, July 10th. ValuEngine lowered shares of Welbilt from a hold rating to a sell rating in a research note on Wednesday, June 12th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $24.43.
NASDAQ:MLND opened at $10.60 on Monday. The company has a fifty day moving average of $12.79. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83. Millendo Therapeutics has a twelve month low of $6.77 and a twelve month high of $17.34.
Millendo Therapeutics (NASDAQ:MLND) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.08). Analysts forecast that Millendo Therapeutics will post -3.25 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in MLND. Great Point Partners LLC bought a new stake in Millendo Therapeutics during the 4th quarter valued at $10,240,000. Worth Venture Partners LLC bought a new stake in Millendo Therapeutics during the 4th quarter valued at $206,000. BlackRock Inc. bought a new stake in Millendo Therapeutics during the 4th quarter valued at $203,000. Tibra Equities Europe Ltd bought a new stake in Millendo Therapeutics during the 1st quarter valued at $303,000. Finally, Private Advisors LLC increased its stake in Millendo Therapeutics by 9.1% during the 1st quarter. Private Advisors LLC now owns 15,263 shares of the company’s stock valued at $229,000 after purchasing an additional 1,279 shares in the last quarter. Institutional investors own 44.07% of the company’s stock.
Millendo Therapeutics Company Profile
Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.
Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.